A carregar...

Dapagliflozin attenuates hypoxia/reoxygenation-caused cardiac dysfunction and oxidative damage through modulation of AMPK

BACKGROUND: Emerging evidence demonstrated dapagliflozin (DAPA), a sodium-glucose cotransporter 2 inhibitor, prevented various cardiovascular events. However, the detailed mechanisms underlying its cardioprotective properties remained largely unknown. RESULTS: In the present study, we sought to inve...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Biosci
Main Authors: Tsai, Kun-Ling, Hsieh, Pei-Ling, Chou, Wan-Ching, Cheng, Hui-Ching, Huang, Yu-Ting, Chan, Shih-Hung
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2021
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7913252/
https://ncbi.nlm.nih.gov/pubmed/33637129
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13578-021-00547-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!